Why rheumatoid arthritis trial monitoring matters
Rheumatoid arthritis is one of the most commercially active therapeutic areas in immunology, with hundreds of trials on ClinicalTrials.gov spanning established biologics, oral small molecules, biosimilars, and an emerging generation of targeted therapies. With multiple blockbuster franchises facing biosimilar competition, the pipeline for next-generation RA therapies is intensely active.
Key signals that rheumatology professionals track:
- New oral programs post-JAK era. TYK2 inhibitors, BTK inhibitors, and novel TNF-targeting agents
- Phase 3 head-to-head trials comparing new mechanisms against established biologics
- Biosimilar entry programs that reshape market dynamics for approved agents
- Combination regimens and treat-to-target protocol trials
- CAR-T and cell therapy first-in-human studies entering RA and related autoimmune conditions
- Label expansion programs, approved RA agents entering trials for other rheumatic diseases (PsA, AS, SLE)
Get daily RA trial digest
Set your profile once. Receive a clean digest every morning with new rheumatoid arthritis trials and updates matching your criteria.
Get the Free DigestA primary completion date pushed out, enrollment cut, or a primary endpoint changed in the last 90 days. Active trials only.
| Trial | Warning signs | Status |
|---|---|---|
| Faecal Microbiota Transplantation in Patients With Refractory Rheumatoid… NCT07639177 | Primary completion moved at least 3 years later | Recruiting |
13 more on the Trials at Risk page. See which trials →
Phase 2 and Phase 3 trials with a primary completion date in the next 180 days, as ClinicalTrials.gov estimates it today. Active trials only.
| Trial | Scheduled | Phase |
|---|---|---|
| Venlafaxine as Adjunct Therapy in Rheumatoid Arthritis NCT07497282 | Oct 26, 2026 · Estimated | Phase 2 |
19 more on the Completions page. See the calendar →
What DataLookout monitors for rheumatoid arthritis
DataLookout pulls directly from the ClinicalTrials.gov API every day. For a rheumatoid arthritis watch profile, you can configure:
- Condition keywords: "rheumatoid arthritis", "RA", "early rheumatoid arthritis", "refractory RA", "anti-CCP", "seronegative RA"
- Mechanism keywords: "JAK inhibitor", "TNF inhibitor", "IL-6", "biologic DMARD", "TYK2", "BTK inhibitor", "CAR-T autoimmune"
- Phase filter: Phase 2 proof-of-concept, Phase 3 pivotal, or all phases
- Sponsor filter: Industry-sponsored programs for competitive intelligence, or all sponsors
- Status filter: Recruiting only, all active, or any status
What DataLookout adds to ClinicalTrials.gov
ClinicalTrials.gov RSS feeds tell you that a study record was updated. DataLookout compares each record against the previous day across 13 tracked fields and tells you which one changed, with the old and new values, for every Rheumatoid Arthritis trial on your watchlist. Each change is marked Stopped, Notable or Minor, so a trial being terminated does not read the same as a few sites being added.
Who uses rheumatoid arthritis trial monitoring
Immunology pharma BD and strategy teams
Business development teams at immunology-focused pharmaceutical companies track the RA pipeline to identify partnership, licensing, and acquisition targets. With the post-JAK competitive landscape intensifying, knowing which new mechanisms are entering Phase 2, and which sponsors are behind them, is critical for strategic planning.
Rheumatology-focused biotech investors
Investors following the autoimmune space track Phase 2 initiations and Phase 3 readouts as major catalysts. A Phase 3 start in a differentiated RA mechanism often precedes a major financing event or M&A transaction by 12–24 months.
Medical affairs and clinical teams at established players
Medical affairs professionals at companies with approved RA therapies track competitors' clinical programs to anticipate label changes, new combinations, and evolving treatment guidelines. Daily trial intelligence informs medical education, advisory board priorities, and publication strategy.
Rheumatology CROs and site networks
CROs and research site networks specializing in rheumatology track new RA trial registrations to identify upcoming studies that will need patient recruitment support, site qualification, and data management, often months before the sponsor issues a formal RFP.
Frequently asked questions
How current is the rheumatoid arthritis trial data?
Our pipeline fetches from ClinicalTrials.gov every morning. Studies posted or updated in the preceding 24 hours appear in that day's digest. ClinicalTrials.gov is updated as sponsors submit new registrations or amendments, typically within 24–48 hours.
Can I monitor RA and related conditions like PsA and AS together?
Yes. On Pro ($49/month, or $490/year), you can create up to 10 sponsor and 10 disease watchlists. You might configure one for RA, one for psoriatic arthritis (PsA), and one for ankylosing spondylitis (AS), each delivering a targeted daily digest. Alternatively, combine keywords across conditions in a single broad immunology profile.
Does DataLookout include biosimilar trials?
Yes, biosimilar trials registered on ClinicalTrials.gov are included. You can track biosimilar programs by adding terms like "biosimilar" or the reference product name (e.g., "adalimumab biosimilar", "etanercept biosimilar") to your condition keyword profile.
Does DataLookout cover international RA trials?
ClinicalTrials.gov includes internationally conducted trials. Most major industry-sponsored Phase 3 RA trials have multinational enrollment and are registered on ClinicalTrials.gov, making them visible in your daily digest.
468 active trials, 238 recruiting.
Industry sponsors run 171 of these trials. The rest are run by universities, hospitals, government bodies and other non-commercial sponsors. The table below lists the 5 largest of 96.
| Top industry sponsor | Active trials |
|---|---|
| Zimmer Biomet | 25 |
| Medacta International SA | 9 |
| Aesculap AG | 7 |
| Bristol-Myers Squibb | 5 |
| Stryker Trauma and Extremities | 5 |
View the full Rheumatoid Arthritis pipeline on the dashboard
| Trial | Status | Latest tracked change | Seen |
|---|---|---|---|
| A Study to Investigate Efficacy and Safety of AZD1163 in Participants With… NCT07276581 | Recruiting | Trial sites expanded: 144 → 147 locations | 2026-10-10 |
| Pain Neuroscience Education and Vagus Nerve Stimulation on Recovery in… NCT07274124 | Recruiting | Enrollment increased: 36 → 42 participants | 2026-10-10 |
| A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid… NCT06972446 | Recruiting | Interventions modified | 2026-10-09 |
| Probiotics in Adults With Rheumatoid Arthritis NCT07304505 | Active, Not Recruiting | Completion pushed from Mar 2026 to Nov 2026 | 2026-10-07 |
| MethMax Trial: MAXimising the METHotrexate Therapy Potential in Patients With… NCT06649136 | Recruiting | Completion pushed from Sep 30, 2026 to Jun 7, 2027 | 2026-10-07 |
Each trial page shows every change DataLookout has recorded for that trial.
DataLookout checks ClinicalTrials.gov every day and records what changed on each trial: status, enrollment, phase, primary endpoint, completion dates, sites, sponsor, and the stated reason a trial stopped. Add a sponsor or a disease to your watchlist, or save any search, and the changes arrive in a daily or weekly email digest.
Free, $0 forever: 1 sponsor + 1 disease watchlist, 1 saved search in your email digest, track up to 5 individual trials, daily change detection, Trials at Risk (top 2 trials), the weekly report (top 3 trials). No credit card.
Pro, $49/month or $490/year: 10 sponsor + 10 disease watchlists, 10 saved searches in your email digest, track up to 25 individual trials, full Trials at Risk list, Completions calendar, the full weekly report, landscape reports, CSV export.